Up a few cents PM let's see if it moves up from these still near all-time low's, can Galena and non-shorting actual "investors" finally get a break?
I'm not happy about being down so long but this is a company doing things for society we can all feed very good about -- unlike the shorting slime who should pick equally slimy co's but hey, our capitalist system makes room for slime too!
They have a right to try to tear down co's working to save lives!
Hope I or my loved ones don't ever need these treatments but sure is good to know they're being developed, just in case:
Here's another version, GL folks!
Galena Biopharma Completes Over-Enrollment Of NeuVax(TM) (Nelipepimut-S) Phase 3 PRESENT Clinical Trial *
Tuesday 04/14/2015 07:21 AM ET - Dow Jones News
Galena Biopharma Completes Over-Enrollment of NeuVax(TM) (nelipepimut-S) Phase 3 PRESENT Clinical Trial
Tuesday 04/14/2015 07:21 AM ET - GlobeNewsWire via Dow Jones News
Galena Biopharma Completes Over-Enrollment of NeuVax(TM) (nelipepimut-S) Phase 3 PRESENT Clinical Trial PRESENT Clinical Trial Milestone Achieved With 758 Patients Enrolled PORTLAND, Ore., April 14, 2015 (GLOBE NEWSWIRE) -- Galena Biopharma, Inc. (Nasdaq:GALE), a biopharmaceutical company developing and commercializing innovative, targeted oncology therapeutics that address major medical needs across the full spectrum of cancer care, today announced the completion of enrollment in the NeuVax(TM) (nelipepimut-S) Phase 3 PRESENT (Prevention of Recurrence in Early-Stage, Node-Positive Breast Cancer with Low to Intermediate HER2 Expression with NeuVax Treatment) clinical trial. NeuVax(TM) is a first-in-class, HER2-directed cancer immunotherapy under evaluation to prevent breast cancer recurrence after standard of care treatment in the adjuvant setting.
